Session » Systemic Lupus Erythematosus – Animal Models - Poster II
-
Abstract Number: 2781
Immunization with ApoB100 Peptide Vaccine Reduces Atherosclerosis Development in a Mouse Model of Systemic Lupus Erythematosus
-
Abstract Number: 2782
Bortezomib Treatment Prevents Glomerulosclerosis Associated with Lupus Nephritis in a Murine Model through Suppressive Effects on the Immune and Renin-Angiotensin Systems
-
Abstract Number: 2783
Human Mesenchymal Stem Cells from Different Tissues Exert Distinct Therapeutic Effect on Systemic Lupus Erythematosus
-
Abstract Number: 2784
Mesenchymal Stem Cells Ameliorate Lupus By Promoting T Cell Apoptosis Via Bcl-2/Bim Independent Pathway in MRL/Lpr Mice
-
Abstract Number: 2786
The Janus Kinase Inhibitor Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
-
Abstract Number: 2787
Bortezomib Treatment Induces Higher Mortality Rate in Lupus Model Mice with High Disease Activity
-
Abstract Number: 2788
Suppression of IL-1 Signaling Ameliorates Dermatitis in a Murine Model of Systemic Lupus Erythematosus
-
Abstract Number: 2789
Novel Glucocorticoid Prodrug Effectively Attenuates Late Stage Lupus Nephritis with Improved Safety Profile